General Hospital Psychiatry
August 5, 2025
Jennie Hultgren, Matthias H Hafsteinsson, Joel Gruneau Brulin
13 citations
Our findings did not support that the amount of therapy hours influence depressive outcomes in PAT. However, this interpretation should be made with caution due to small sample sizes, heterogeneity, and poor reporting of the therapeutic component across studies. Future research should apply greater methodological rigor and standardized reporting of therapy to clarify its role in PAT.
Frontiers in Systems Neuroscience
August 5, 2025
Dotun Adeleye Adeyinka, Donelson R. Forsyth, Suzanne Currie et al.
7 citations
Psilocybin, a compound found in Psilocybe mushrooms, is emerging as a promising treatment for neurodegenerative and psychiatric disorders, including major depressive disorder. Its potential therapeutic effects stem from promoting neuroprotection, neurogenesis, and neuroplasticity, key factors in brain health. Psilocybin could help combat mild neurodegeneration by increasing synaptic density and...
The Brown University Psychopharmacology Update
August 4, 2025
Use of selective serotonin reuptake inhibitor (SSRI) antidepressants has been associated with reduced intensity of emotional experience. Conversely, some research has shown that use of psilocybin in patients with depression leads to an increase in responsiveness to emotional face stimuli, suggesting that the psychedelic generates a transient elevation in mood. Investigators conducted a...
Journal of Psychoactive Drugs
August 4, 2025
Meredith C Meacham, Maha N. Mian, Ralph C. Wang et al.
2 citations
Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aims of this study are to characterize subgroups of lifetime hallucinogen use and to identify sociodemographic correlates of these subgroups. Latent class models were fit using 2021-2022 National Survey on Drug Use and Health (NSDUH) data on a...
Frontiers in Psychiatry
August 4, 2025
Wierzbicka Małgorzata, Renata Kopczyk, Alexander L. Gerlach et al.
1 citation
Depression prevalence is markedly elevated in oncological patients, particularly among head and neck cancer (HNC) cohorts, who face twice the prevalence of major depressive disorder (MDD) compared to other cancer populations. MDD in this context independently predicts poorer clinical outcomes and increased morbidity. HNC management often involves acute surgical interventions with disfiguring...
Cureus
August 1, 2025
Brett Hughes, Soz Mirza, Manasi Ponamala et al.
The stresses of the Coronavirus Disease of 2019 (COVID-19) pandemic highlighted the burden of psychiatric disorders within the pediatric population, revealing a pre-existing need for rapid-onset therapies that have since driven efforts to expand effective therapeutic interventions. In this narrative review, we utilized the Preferred Reporting Items for Systematic reviews and Meta-Analysis...
August 1, 2025
Annabelle Swain
This literature review looks at how psilocybin, the active compound in "magic mushrooms," can help people deal with death anxiety; the deep fear of dying or losing control that shows up in lots of mental health struggles. While traditional treatments like SSRIs and talk therapy work for some people, they don't always get to the root of the problem. Psilocybin works differently. It changes brain...
The International Journal of Neuropsychopharmacology
August 1, 2025
Siegfried Kasper
Abstract Background Psycholicibin is now studied in clinical settings. Aims & Objectives To elaborate if side effects are part of the therapeutic process. Method Literature overview and personal statement. Results The recent development of the socalled “psychedelics” reminds us that unfortunately some medications which we used in psychiatry have a large burden of side effects, like the...
The International Journal of Neuropsychopharmacology
August 1, 2025
N Acevdo, David Castle, Susan L. Rossell
Abstract Background Obsessive compulsive disorder (OCD), body dysmorphic disorder (BDD), and anorexia nervosa (AN) are some of the most debilitating and chronic mental health conditions, with impairments across multiple domains of functioning, leading to poor quality of life and well-being. These conditions share overlapping psychopathological determinants in terms of cognitive-behavioural...
The International Journal of Neuropsychopharmacology
August 1, 2025
Cassandra J. Hatzipantelis, David E. Olson, Danielle S. Stolzenberg
Abstract Background Peripartum mood disorders (PMDs) are a major public health concern; they present in 20% of birthing parents and are responsible for 1 in 4 maternal deaths in the United States. The psychedelic antidepressant psilocybin (PSI) increases social connectedness, self-compassion, and has strong clinical transdiagnostic efficacy for mental illness – making it a candidate treatment...
The International Journal of Neuropsychopharmacology
August 1, 2025
Bernard Lerer, T. Tal, Ilana Pogodin et al.
Abstract Background The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophrenia, is limited by possible adverse effects, including perceptual disturbances and psychosis, which require administration in controlled clinical environments. This study investigates the potential synergistic benefits of combining...
The International Journal of Neuropsychopharmacology
August 1, 2025
Andrew S. Gibbons, Paul Liknaitzky, Suresh Sundram
Abstract Background Early intervention and management of Generalised Anxiety Disorder (GAD) is essential to effectively reduce both symptom severity and the risk of developing other psychiatric disorders. However, current first-line treatments are only about 50% effective, with high rates of relapse and many adverse effects. Psychedelic medicines, such as psilocybin, have emerged as promising...
The International Journal of Neuropsychopharmacology
August 1, 2025
Yana Babii, C. Barbara, Dorota Bederska‐łojewska et al.
Abstract Background Numerous data indicates that hallucinogens from various groups such as ketamine, scopolamine or psilocybin exert rapid antidepressant effects in both preclinical and clinical studies. Group II glutamate (mGlu) metabotropic receptor antagonists also show rapid antidepressant efficacy in animal studies, moreover we have shown that mGluR2/3 antagonist, LY341495 is able to...
The International Journal of Neuropsychopharmacology
August 1, 2025
Giovanni Martinotti, Clara Cavallotto, Giacomo D’andrea et al.
Abstract Background Among the innovative treatments investigated for depression, psilocybin appears to play an extremely promising role, with several studies showing remission rates up to 70% in patients with treatment-resistant depression (TRD) treated with protocols involving a single or double dose administration [1,2]. Psilocybin is a psychedelic compound belonging to the tryptamine class,...
The International Journal of Neuropsychopharmacology
August 1, 2025
Valeria Bruno, Bruce Richardson, Martha López-canul et al.
Abstract Background Recent years have seen renewed scientific interest in psychedelics, including psilocybin, for their potential in treating neuropsychiatric disorders. However, the reward-related properties and behavioral impacts of a high dose of psilocybin remain insufficiently explored. Aims & Objectives Assessing the potential rewarding properties of a high dose of psilocybin (10 mg/kg...
The International Journal of Neuropsychopharmacology
August 1, 2025
Nicolo Fabila, Nimshitha Pavathuparambil Abdul Manaph, V Rudkowsky et al.
Abstract Background Binge eating disorder (BED) is the most prevalent eating disorder, often associated with metabolic syndrome and other mental health comorbidities. Despite its impact, current treatment options remain limited. BED is associated with compulsive intake of foods typically high in fat and sugar, as well as neuroplastic changes in brain regions such as the nucleus accumbens,...
The International Journal of Neuropsychopharmacology
August 1, 2025
B. D. Richardson, Marco Pileggi, Thomas Prudhomme et al.
Abstract Background Psychedelics hold potential as therapeutics in psychological disorders. Even if they primarily act on 5-HT2A receptors, their mechanisms and effects on the brain are not well understood. Simply activating 5-HT2A receptors does not induce psychedelic effects. For example, psilocybin and lisuride both bind to 5-HT2A receptors, but only psilocybin induces hallucinogenic...
International Journal of Drug Policy
August 1, 2025
Karla Hitchins, James P. Reynolds
1 citation
BACKGROUND: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently illegal in the UK. Less is known about how people form their attitudes towards psilocybin policies. OBJECTIVES: To explore whether beliefs about the benefits and safety of psilocybin influence support for psilocybin policies. METHODS: In an online...
The International Journal of Neuropsychopharmacology
August 1, 2025
Susan Meikle, Olivia Carter, Paul Liknaitzky et al.
Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left with residual symptoms such as impairments in cognition and social functioning. Emerging psychedelic therapies show promise for treating depression but require further research. Aims & Objectives This pilot study aimed to evaluate the feasibility,...
The International Journal of Neuropsychopharmacology
August 1, 2025
Thibault Renoir, James J Gattuso, Bilgenur Bezcioglu et al.
Abstract Background The evident limitations of current treatments for depression, anxiety and obsessive-compulsive disorder (OCD), underscore the need for a paradigm shift in how we understand and treat these disorders. There is enormous public and research enthusiasm for the potential that psychedelic drugs like psilocybin, the psychoactive compound produced by “magic mushrooms” will drive a...